Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Orforglipron and Retatrutide — mechanism, side effects, legal status, and pricing.
Orforglipron (brand name Foundayo) is Eli Lilly's oral non-peptide small-molecule GLP-1 receptor agonist. Unlike oral semaglutide (Rybelsus), it does not require the SNAC absorption enhancer or fasting/water restrictions — it can be taken any time of day. Not a peptide.
Orforglipron
Retatrutide
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Orforglipron
No pricing data yet.
Check Orforglipron prices →Retatrutide
COA corpus from Disclosed Labs — independently tested batches only.
Orforglipron
2
COAs
99.3%
Avg purity
2
Labs
Retatrutide
413
COAs
99.7%
Avg purity
17
Labs
ATTAIN-1 Phase 3 (n=3,127, non-diabetic obesity): mean body-weight change -11.2% with 36 mg at week 72 vs -2.1% placebo; ~59.6% of the 36 mg arm achieved ≥10% loss (Wharton et al., NEJM 2025). ATTAIN-2 (T2D obesity) and the ACHIEVE program (T2D glycemic control) were also positive. FDA approved April 1, 2026 as Foundayo under the Commissioner's National Priority Voucher program for adults with obesity or overweight with ≥1 weight-related comorbidity — the first oral small-molecule GLP-1 RA approved in the US.
Key references
Phase 2 obesity trial (Jastreboff et al., NEJM 2023; PMID 37366315) demonstrated up to 24.2% body weight loss at 48 weeks at the 12 mg dose, exceeding both semaglutide and tirzepatide. A Phase 2 type 2 diabetes trial (Rosenstock et al., Lancet 2023; PMID 37385280) showed robust HbA1c and weight reductions vs. placebo and dulaglutide. A Phase 2a MASLD trial (Sanyal et al., Nat Med 2024; PMID 38858523) demonstrated significant reductions in hepatic steatosis driven by glucagon receptor activation. Phase 3 TRIUMPH trials are ongoing (Eli Lilly), with results expected 2025–2026. Retatrutide is NOT FDA-approved as of April 2026 — it remains investigational.
Key references
Orforglipron and Retatrutide are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs